Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial

N. Vey, AS. Chretien, PY. Dumas, C. Recher, L. Gastaud, B. Lioure, CE. Bulabois, C. Pautas, JP. Marolleau, S. Lepretre, E. Raffoux, X. Thomas, Y. Hichri, C. Bonmati, B. Quesnel, P. Rousselot, E. Jourdan, JV. Malfuson, G. Guillerm, JH. Bourhis, M. Ojeda-Uribe, M. Hunault, A. Ben Amara, MS. Rouvière, N. Boucherit, P. André, C. Preudhomme, N. Dulphy, A. Toubert, N. Ifrah, D. Olive, H. Dombret
doi: https://doi.org/10.1101/2024.08.23.24312477

Article Information

doi 
https://doi.org/10.1101/2024.08.23.24312477
History 
  • August 23, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. N. Vey1,*,#,
  2. AS. Chretien1,*,#,
  3. PY. Dumas2,
  4. C. Recher3,
  5. L. Gastaud4,
  6. B. Lioure5,
  7. CE. Bulabois6,
  8. C. Pautas7,
  9. JP. Marolleau8,
  10. S. Lepretre9,
  11. E. Raffoux10,
  12. X. Thomas11,
  13. Y. Hichri12,
  14. C. Bonmati13,
  15. B. Quesnel14,
  16. P. Rousselot15,
  17. E. Jourdan16,
  18. JV. Malfuson17,
  19. G. Guillerm18,
  20. JH. Bourhis19,
  21. M. Ojeda-Uribe20,
  22. M. Hunault21,
  23. A. Ben Amara1,
  24. MS. Rouvière1,
  25. N. Boucherit1,
  26. P. André22,
  27. C. Preudhomme14,
  28. N. Dulphy10,
  29. A. Toubert10,
  30. N. Ifrah21,
  31. D. Olive1,* and
  32. H. Dombret10,*
  1. 1Institut Paoli-Calmettes, Marseille, France
  2. 2CHU Bordeaux, Service d’Hématologie Clinique et de Thérapie Cellulaire, F-33000, Bordeaux, France
  3. 3CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, France
  4. 4Centre Antoine Lacassagne, Nice, France
  5. 5CHU, Institut de CANcérologie de Strasbourg Europe, ICANS, France
  6. 6CHU de Grenoble, France
  7. 7Hopital Henri Mondor, Créteil, France
  8. 8CHU Amiens, France
  9. 9Centre Henri Becquerel, Rouen, France
  10. 10Hôpital Saint Louis, Paris, France
  11. 11CHU Lyon Sud, France
  12. 12CHU Montpellier, France
  13. 13CHU Nancy, France
  14. 14CHRU Lille, France
  15. 15CH de Versailles, France,
  16. 16CHU de Nîmes, France
  17. 17Hôpital Militaire Percy, Clamart, France
  18. 18CHU de Brest, France
  19. 19Institut Gustave Roussy, Villejuif, France
  20. 20CH Mulhouse, France
  21. 21CHU Angers, France
  22. 22Innate Pharma, Marseille, France
  1. ↵#Correspondence and requests for materials should be addressed to Norbert Vey and Anne-Sophie Chretien; email: anne-sophie.chretien{at}inserm.fr.

  1. ↵* Equally contributed to this work.

Back to top
Posted August 23, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial
N. Vey, AS. Chretien, PY. Dumas, C. Recher, L. Gastaud, B. Lioure, CE. Bulabois, C. Pautas, JP. Marolleau, S. Lepretre, E. Raffoux, X. Thomas, Y. Hichri, C. Bonmati, B. Quesnel, P. Rousselot, E. Jourdan, JV. Malfuson, G. Guillerm, JH. Bourhis, M. Ojeda-Uribe, M. Hunault, A. Ben Amara, MS. Rouvière, N. Boucherit, P. André, C. Preudhomme, N. Dulphy, A. Toubert, N. Ifrah, D. Olive, H. Dombret
medRxiv 2024.08.23.24312477; doi: https://doi.org/10.1101/2024.08.23.24312477
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area